We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

133 hedge funds and large institutions have $385M invested in Progenics Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 43 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

29% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $886K

10% more funds holding

Funds holding: 121133 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 43

23% less capital invested

Capital invested by funds: $501M → $385M (-$116M)

Holders
133
Holders Change
+12
Holders Change %
+9.92%
% of All Funds
3.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
43
Reduced
43
Closed
12
Calls
$1.14M
Puts
$886K
Net Calls
+$254K
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$221K +$297K +38,652 +110,434%
WAM
77
Wolverine Asset Management
Illinois
$217K -$709K -92,400 -71%
CPA
78
Cowen Prime Advisors
New York
$217K
AL
79
Airain Ltd
Guernsey
$212K +$285K +37,114 New
UBS AM
80
UBS AM
Illinois
$211K +$21.5K +2,800 +8%
DekaBank Deutsche Girozentrale
81
DekaBank Deutsche Girozentrale
Germany
$200K +$7.67K +1,000 +3%
VKH
82
Virtu KCG Holdings
New York
$195K -$97.6K -12,725 -27%
VOYA Investment Management
83
VOYA Investment Management
Georgia
$182K -$69.6K -9,076 -22%
AIM
84
Ada Investment Management
New York
$180K +$243K +31,709 New
CSS
85
Cubist Systematic Strategies
Connecticut
$171K -$801K -104,340 -78%
VRS
86
Virginia Retirement Systems
Virginia
$156K +$209K +27,300 New
Bank of America
87
Bank of America
North Carolina
$152K -$615K -80,134 -75%
DIA
88
Denver Investment Advisors
Colorado
$142K -$6.54K -852 -3%
William Blair & Company
89
William Blair & Company
Illinois
$137K
DSC
90
Duncker Streett & Co
Missouri
$136K -$11.5K -1,500 -6%
PPA
91
Parametric Portfolio Associates
Washington
$130K -$288K -37,530 -62%
SKK
92
Shepherd Kaplan Krochuk
Massachusetts
$117K +$157K +20,497 New
Asset Management One
93
Asset Management One
Japan
$115K +$154K +20,071 New
EMG
94
Ellington Management Group
Connecticut
$115K +$155K +20,146 New
Wells Fargo
95
Wells Fargo
California
$113K -$131K -17,088 -46%
Barclays
96
Barclays
United Kingdom
$107K -$512K -66,783 -76%
PIC
97
PCJ Investment Counsel
Ontario, Canada
$101K +$38.6K +5,030 +40%
D.E. Shaw & Co
98
D.E. Shaw & Co
New York
$93K -$24.5K -3,196 -16%
RCM
99
Rotella Capital Management
Washington
$93K +$32.6K +4,242 +35%
SG Americas Securities
100
SG Americas Securities
New York
$93K +$125K +16,278 New

PGNX Hedge Fund Activity: Q3 2015 in Review

133 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2015, worth a combined $385M — down 23% from $501M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PGNX positions and 12 closed out — a net gain of 12 holders — while 43 added to existing stakes and 43 trimmed.

The largest buyer was Bogle Investment Management, opening a new position worth an estimated $6.06M. The largest seller was Wellington Management Group, cutting an estimated $6.12M.

  • 133 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2015, up from 121 in Q2 2015.
  • Funds reported $385M of Progenics Pharmaceuticals Inc stock for Q3 2015, down 23% quarter-over-quarter.
  • 24 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2015 and 12 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2015 was Bogle Investment Management, an estimated $6.06M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2015 was Wellington Management Group, an estimated $6.12M sold.

Based on aggregated 13F filings for Q3 2015.